4//SEC Filing
Mazur Leonard L 4
Accession 0001213900-25-090602
CIK 0001506251other
Filed
Sep 22, 8:00 PM ET
Accepted
Sep 23, 4:05 PM ET
Size
25.8 KB
Accession
0001213900-25-090602
Insider Transaction Report
Form 4
Mazur Leonard L
DirectorChief Executive Officer
Transactions
- Disposition to Issuer
Warrant to Purchase Common Stock
2025-08-08−125,490→ 0 totalExercise: $28.75Exp: 2025-08-14→ Common Stock (125,490 underlying) - Award
Warrant to Purchase Common Stock
2025-08-08+89,388→ 89,388 totalExercise: $19.25Exp: 2026-09-27→ Common Stock (89,388 underlying) - Award
Warrant to Purchase Common Stock
2025-08-08+125,490→ 125,490 totalExercise: $28.75Exp: 2026-08-14→ Common Stock (125,490 underlying) - Disposition to Issuer
Warrant to Purchase Common Stock
2025-08-08−89,388→ 0 totalExercise: $19.25Exp: 2025-09-27→ Common Stock (89,388 underlying)
Holdings
- 410,214
Common Stock
- 22,000
Stock Option (Right to Purchase Common Stock)
Exercise: $31.25Exp: 2032-10-04→ Common Stock (22,000 underlying) - 24,000
Stock Option (Right to Purchase Common Stock)
Exercise: $9.50Exp: 2034-11-07→ Common Stock (24,000 underlying) - 26,000
Stock Option (Right to Purchase Common Stock)
Exercise: $51.00Exp: 2031-10-11→ Common Stock (26,000 underlying) - 7,000
Stock Option (Right to Purchase Common Stock)
Exercise: $16.75Exp: 2029-10-08→ Common Stock (7,000 underlying) - 8,000
Stock Option (Right to Purchase Common Stock)
Exercise: $25.25Exp: 2030-10-06→ Common Stock (8,000 underlying) - 1,600
Stock Option (Right to Purchase Common Stock)
Exercise: $86.25Exp: 2027-09-13→ Common Stock (1,600 underlying) - 6,000
Stock Option (Right to Purchase Common Stock)
Exercise: $40.50Exp: 2028-09-04→ Common Stock (6,000 underlying) - 22,000
Stock Option (Right to Purchase Common Stock)
Exercise: $17.50Exp: 2033-10-10→ Common Stock (22,000 underlying) - 12,000
Stock Option (Right to Purchase Common Stock)
Exercise: $50.00Exp: 2031-07-22→ Common Stock (12,000 underlying)
Footnotes (6)
- [F1]The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately.
- [F2]The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately.
- [F3]The options were granted on November 7, 2024. The options vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
- [F4]The options were granted on October 10, 2023. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
- [F5]The options were granted on October 4, 2022. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
- [F6]The options are vested in full and exercisable immediately.
Documents
Issuer
Citius Pharmaceuticals, Inc.
CIK 0001506251
Entity typeother
Related Parties
1- filerCIK 0001463414
Filing Metadata
- Form type
- 4
- Filed
- Sep 22, 8:00 PM ET
- Accepted
- Sep 23, 4:05 PM ET
- Size
- 25.8 KB